Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EmyriaASX:EMD -2.08% Days Sales Outstanding is 50.86 as of Jun. 2026, which is 124% above its 10-year median of 22.66. The stock has 4 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Emyria ranks better than 54.67% on this metric.
Emyria's average Accounts Receivable for the
six
months ended in Jun. 2026 was A$0.65 Mil. Emyria's Revenue for the
six
months ended in Jun. 2026 was A$2.33 Mil.
Hence, Emyria's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 50.86.
The historical rank and industry rank for Emyria's Days Sales Outstanding or its related term are showing as below:
ASX:EMD'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.41 Med: 22.66 Max: 41.25
Current: 41.25
During the past 8 years, Emyria's highest Days Sales Outstanding was 41.25. The lowest was 6.41. And the median was 22.66.
ASX:EMD's Days Sales Outstanding is ranked better than 54.67% of 664
companies
in the Healthcare Providers & Services industry
Industry Median: 45.78
vs ASX:EMD: 41.25
Emyria's Days Sales Outstanding
declined
from Jun. 2025 (59.71) to Jun. 2026 (50.86).
Emyria (ASX:EMD) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Emyria Days Sales Outstanding Related Terms
Emyria Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Emyria's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EMD vs VEEV, BTSG, TEM: Days Sales Outstanding Comparison
For the Health Information Services subindustry, Emyria's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emyria Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Emyria's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Emyria's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emyria (ASX:EMD) has a Days Sales Outstanding of 50.86 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Emyria and its competitors. This is 124% above median its historical median of 22.66. Over the past decade, Emyria's Days Sales Outstanding has ranged from 6.41 to 41.25. According to the industry distribution chart, Emyria ranks #301 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 45.3%.
Is Emyria's Days Sales Outstanding too high?
Emyria's current Days Sales Outstanding of 50.86 is 124% above median its 10-year median of 22.66. Over the past 10 years, this metric has ranged from a low of 6.41 to a high of 41.25. The Healthcare Providers & Services industry median Days Sales Outstanding is 45.78. Emyria's value of 50.86 is 11.1% above this industry median. Based on the distribution chart, Emyria ranks #301 out of 664 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Emyria's Days Sales Outstanding compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Emyria ranks #301 out of 664 companies for Days Sales Outstanding. This puts Emyria in the upper half of its industry. The industry median Days Sales Outstanding is 45.78. Emyria's value of 50.86 is 11.1% above this benchmark. Historically, Emyria's own Days Sales Outstanding has ranged from 6.41 to 41.25 over the past decade. While the company's 10-year median is 22.66 vs. the industry median of 45.78, Emyria has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 45.78, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emyria's current Days Sales Outstanding of 50.86 is 11.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Emyria and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 45.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emyria's current Days Sales Outstanding is 50.86, which is 124% above median its own 10-year median of 22.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emyria stock overvalued right now?
Based on GuruFocus' analysis, Emyria (ASX:EMD) is currently considered Fairly Valued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.05 — trading 6% below its estimated fair value. The current Days Sales Outstanding is 50.86, which is 124% above median its 10-year median of 22.66 and 11.1% above the Healthcare Providers & Services industry median of 45.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Emyria (ASX:EMD), the current Days Sales Outstanding is 50.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EMD has been successfully added to your 
